Craig L. Slingluff

21.1k total citations · 3 hit papers
291 papers, 13.4k citations indexed

About

Craig L. Slingluff is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Craig L. Slingluff has authored 291 papers receiving a total of 13.4k indexed citations (citations by other indexed papers that have themselves been cited), including 192 papers in Oncology, 186 papers in Immunology and 116 papers in Molecular Biology. Recurrent topics in Craig L. Slingluff's work include Immunotherapy and Immune Responses (173 papers), Cancer Immunotherapy and Biomarkers (96 papers) and vaccines and immunoinformatics approaches (75 papers). Craig L. Slingluff is often cited by papers focused on Immunotherapy and Immune Responses (173 papers), Cancer Immunotherapy and Biomarkers (96 papers) and vaccines and immunoinformatics approaches (75 papers). Craig L. Slingluff collaborates with scholars based in United States, Netherlands and Sweden. Craig L. Slingluff's co-authors include Víctor H. Engelhard, Hilliard F. Seigler, Donald F. Hunt, Mark E. Smolkin, Gina R. Petroni, Timothy L. Darrow, Donna H. Deacon, James W. Patterson, Kimberly A. Chianese‐Bullock and Jeffrey Shabanowitz and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Craig L. Slingluff

287 papers receiving 13.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment

2009 872 citations Helena Harlin, Yuru Meng et al. Cancer Research profile →
Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase

2002 814 citations Craig L. Slingluff et al. profile →
Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines

1994 677 citations Víctor H. Engelhard, Craig L. Slingluff et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Craig L. Slingluff United States	64	8.6k	7.5k	4.8k	916	850	291	13.4k
Madhav V. Dhodapkar United States	59	7.9k 0.9×	5.8k 0.8×	6.0k 1.2×	563 0.6×	935 1.1×	227	15.1k
Larry W. Kwak United States	61	6.2k 0.7×	4.9k 0.7×	3.9k 0.8×	618 0.7×	1.3k 1.5×	319	12.6k
John G. Gribben United Kingdom	89	10.9k 1.3×	8.4k 1.1×	5.0k 1.0×	886 1.0×	1.3k 1.5×	481	24.1k
Daniel Olive France	72	13.2k 1.5×	7.1k 1.0×	3.6k 0.8×	1.4k 1.6×	1.1k 1.3×	441	19.1k
Philippe Armand United States	60	6.4k 0.7×	8.8k 1.2×	2.4k 0.5×	812 0.9×	606 0.7×	334	17.5k
Peter Brossart Germany	62	6.6k 0.8×	4.5k 0.6×	4.9k 1.0×	1.2k 1.3×	858 1.0×	289	12.3k
Gianluca Gaïdano Italy	73	4.5k 0.5×	9.4k 1.3×	4.7k 1.0×	1.5k 1.7×	823 1.0×	616	20.4k
Wyndham H. Wilson United States	66	4.8k 0.6×	9.0k 1.2×	4.0k 0.8×	832 0.9×	1.2k 1.4×	329	17.6k
Jonathan Cebon Australia	62	6.6k 0.8×	6.3k 0.8×	4.7k 1.0×	906 1.0×	561 0.7×	278	13.6k
Crystal L. Mackall United States	61	8.5k 1.0×	7.1k 1.0×	3.2k 0.7×	1.3k 1.4×	459 0.5×	168	16.1k

Countries citing papers authored by Craig L. Slingluff

Since Specialization

Citations

This map shows the geographic impact of Craig L. Slingluff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Craig L. Slingluff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Craig L. Slingluff more than expected).

Fields of papers citing papers by Craig L. Slingluff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Craig L. Slingluff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Craig L. Slingluff. The network helps show where Craig L. Slingluff may publish in the future.

Co-authorship network of co-authors of Craig L. Slingluff

This figure shows the co-authorship network connecting the top 25 collaborators of Craig L. Slingluff. A scholar is included among the top collaborators of Craig L. Slingluff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Craig L. Slingluff. Craig L. Slingluff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jin, Ruyun, et al.. (2024). Adverse Events as a Function of Biological Sex in a Multicenter Clinical Trial of Melanoma Vaccines. Cancers. 16(22). 3882–3882. 1 indexed citations

Lynch, Kevin, Yinin Hu, Norma E. Farrow, et al.. (2022). Regional control after precision lymph node dissection for clinically evident melanoma metastasis. Journal of Surgical Oncology. 127(1). 140–147. 1 indexed citations

Sharib, Jeremy, Craig L. Slingluff, & Georgia M. Beasley. (2021). Melanoma trials that defined surgical management: Overview of trials that established NCCN margin guidelines. Journal of Surgical Oncology. 125(1). 28–33. 3 indexed citations

Pinczewski, Joel, Rebecca C. Obeng, Craig L. Slingluff, & Víctor H. Engelhard. (2021). Phospho-β-catenin expression in primary and metastatic melanomas and in tumor-free visceral tissues, and associations with expression of PD-L1 and PD-L2. Pathology - Research and Practice. 224. 153527–153527. 4 indexed citations

Lynch, Kevin, William J. Kane, Max O. Meneveau, et al.. (2021). A pilot trial of vaccination with Carcinoembryonic antigen and Her2/neu peptides in advanced colorectal cancer. International Journal of Cancer. 150(1). 164–173. 10 indexed citations

Lynch, Kevin, Samuel Young, Max O. Meneveau, et al.. (2021). Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma. Journal for ImmunoTherapy of Cancer. 9(6). e002273–e002273. 75 indexed citations

Melssen, Marit M., Robin S. Lindsay, Anthony B. Rodriguez, et al.. (2021). Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells. Cancer Immunology Research. 9(5). 583–597. 15 indexed citations

Cummings, Kara L., Erin D. Jeffery, Dennis Underwood, et al.. (2021). Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients. Cancer Immunology Research. 9(11). 1327–1341. 4 indexed citations

Mauldin, Ileana S., et al.. (2018). Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Research. 28(3). 237–245. 38 indexed citations

10.

Hsueh, Eddy C., James R. DeBloom, Jonathan Lee, et al.. (2017). Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. Journal of Hematology & Oncology. 10(1). 152–152. 66 indexed citations

11.

Michaels, Alex D., Timothy E. Newhook, Sara J. Adair, et al.. (2017). CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clinical Cancer Research. 24(6). 1415–1425. 81 indexed citations

12.

Hu, Yinin, Puja Shah, George J. Stukenborg, & Craig L. Slingluff. (2015). Utility of sentinel lymph node biopsy for solitary dermal melanomas. Journal of Surgical Oncology. 111(7). 800–807. 7 indexed citations

13.

Zarling, Angela L., Rebecca C. Obeng, A. Nicole Desch, et al.. (2014). MHC-Restricted Phosphopeptides from Insulin Receptor Substrate-2 and CDC25b Offer Broad-Based Immunotherapeutic Agents for Cancer. Cancer Research. 74(23). 6784–6795. 29 indexed citations

14.

Stukenborg, George J., et al.. (2013). Design, Development, and Evaluation of a Novel Retraction Device for Gallbladder Extraction During Laparoscopic Cholecystectomy. Journal of Gastrointestinal Surgery. 18(2). 334–339. 2 indexed citations

15.

Slingluff, Craig L., Charles Lee, Fengmin Zhao, et al.. (2013). A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602). Clinical Cancer Research. 19(15). 4228–4238. 90 indexed citations

16.

Slingluff, Craig L., Gina R. Petroni, David L. Brautigan, et al.. (2013). Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47). Clinical Cancer Research. 19(13). 3611–3620. 28 indexed citations

17.

Clancy‐Thompson, Eleanor, et al.. (2013). Peptide Vaccination in Montanide Adjuvant Induces and GM-CSF Increases CXCR3 and Cutaneous Lymphocyte Antigen Expression by Tumor Antigen–Specific CD8 T Cells. Cancer Immunology Research. 1(5). 332–339. 24 indexed citations

18.

Erdag, Gulsun, Jochen T. Schaefer, Mark E. Smolkin, et al.. (2012). Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma. Cancer Research. 72(5). 1070–1080. 439 indexed citations

19.

Slingluff, Craig L., Gina R. Petroni, Walter C. Olson, et al.. (2009). Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial. Clinical Cancer Research. 15(22). 7036–7044. 129 indexed citations

20.

Harlin, Helena, Yuru Meng, Amy Peterson, et al.. (2009). Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment. Cancer Research. 69(7). 3077–3085. 872 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact